DNA-FACE™ (DNA Fragment Amplification & Concatemeric Expressed Nucleic Acids and Proteins) is a universal biotechnological platform, created with the use of genetic engineering methods, based on directional, ordered amplification of natural or designed DNA fragments, coding for a specific function. This isothermal enzymatic reaction leads to the construction of targeted, concatemeric biological macromolecules, including DNA, RNA, proteins. DNA-FACE™ is applicable to the development of new generation, protein- or mRNA-based vaccines, genetically programmed DNA, RNA, mRNA, proteins and biological drugs, as well as to industrial and environmental processes.
The DNA-FACE™ technology is protected worldwide by 5 granted patents and 6 patent applications. This break-through biotechnology of ordered DNA fragment amplification-expression and construction of genetically programmable artificial proteins provides scientific and economical solutions, unachievable with other known technologies.
The DNA-FACE™ technology is constantly evolving and has a number of implementation possibilities in many areas of medicine. As a result of established research cooperations, every day interactive groups of scientists work on the implementation of technologies in vaccine production, regenerative medicine and environmental remediation. The innovative nature of our technology allows the development of a patent cloud, which guarantees multi-level security of the company's technology.
An innovative new technological platform for multiple applications, including vaccine and biologics drugs construction, based on artificial, concatemeric proteins:
Break-through technology highlights
Construction of artificial proteins with highly increased immunogenicity, obtained using the patented DNA fragment amplification-expression method and a genetically programmable method of concatemeric proteins biosynthesis.
Artificial proteins that do not exist in nature, containing hundreds of epitopes or epitope clusters derived from various antigens or protein segments (bioactive epitopes) in directional concatemers comprise a condensed stimulant which induces an immune response. Implementation of bionanostructures increases the potential number of bioactive epitopes to hundreds of thousands.
Construction of higher order structures – bacteriophages, defective bacteriophages and virions, as well as higher order bionanostructures fused to those proteins.
Selection of the most immunogenic vaccine or the most effective biological drug, as the technology generates multiple series of recombinant constructs.
This technology concept, already proven experimentally, is opening new avenues in genetic engineering.
The ordered amplification of a mini-gene, encoding a peptide (epitope) with a particular biological or chemical function, leads to the amplification of a desirable interaction of the resulting (poly)peptide with a specific ligand. In particular, such poly-epitopic proteins can be used to develop:
A universal biotechnology with multiple applications
A binding module for enzyme cofactors (including cations, anions, organic molecules), such as proteases acting within a wound in order to stop deleterious activities.
Protective poly-epitopic proteins, multiplex modules containing peptides with activators or inhibitors of biological functions for the treatment of molecular, viral and bacterial diseases.
Poly-micro RNA, poly-antisense nucleic acids for the treatment of genetic, molecular, viral and bacterial diseases.
Poly-epitopic proteins containing multimers of peptide hormones or biologically active fragments of signaling proteins and those that stimulate tissue regeneration. Constructed poly-epitopic proteins, placed in a wound, would gradually release biologically active peptides under the influence of proteinases, stimulating the regeneration of tissue.
Poly-epitopic proteins containing modules for toxic metals chelation for human and animal detoxification, as well as environmental remediation.
The poly-epitopic protein can be immobilized on macromolecular carriers, such as microorganisms, cells, bacteria, bacteriophages, viruses, defective virions, auto aggregating proteins or nanoparticles. The immobilization may be performed using genetic or chemical means. Immobilized polyepitopic proteins may magnify the effect of the envisaged uses mentioned above.
BioVentures Institute technology has the potential to optimize development of vaccines, innovative proteins- and nucleic acids-based vaccines as well as drugs in a profitable way – developing rapidly new technological avenues, based on our universal technology, and decreasing the cost of goods - it represents vast commercial opportunity.
Speed and cost effectiveness
The technology is based on precisley programmed bio- or chemically active peptides, thus it's targets are are are adressed with very high affinity and specificity.
Bio- or chemically active peptides selected for the construction of concatemeric proteins form multiple unit-containing polymers, which cooperatively highly enhance the sensitivity of molecular interactions.
The technology is covered by 5 patents and 6 patent applications and thusevery new development is automatically protected.